286 related articles for article (PubMed ID: 34503088)
1. Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy.
Lamure S; Van Laethem F; De Verbizier D; Lozano C; Gehlkopf E; Tudesq JJ; Serrand C; Benzaoui M; Kanouni T; Quintard A; De Vos J; Tchernonog E; Platon L; Ayrignac X; Ceballos P; Sirvent A; François M; Guedon H; Quittet P; Mongellaz C; Conte A; Herbaux C; Bret C; Taylor N; Dardalhon V; Cartron G
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503088
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers.
Karthikeyan B; Sunder SS; Puzanov I; Olejniczak SH; Pokharel S; Sharma UC
Commun Med (Lond); 2024 Jun; 4(1):116. PubMed ID: 38871977
[TBL] [Abstract][Full Text] [Related]
3. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
4. Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients.
Nydegger A; Novak U; Kronig MN; Legros M; Zeerleder S; Banz Y; Bacher U; Pabst T
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885182
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
7. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
9. Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.
Schaefer A; Huang Y; Kittai A; Maakaron JE; Saygin C; Brammer J; Penza S; Saad A; Jaglowski SM; William BM
Cancer Manag Res; 2021; 13():8901-8906. PubMed ID: 34876852
[TBL] [Abstract][Full Text] [Related]
10. Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting.
Thakkar A; Cui Z; Peeke SZ; Shah N; Pradhan K; Lombardo A; Khatun F; Mustafa J; De Castro A; Gillick K; Joseph F; Naik A; Rahman S; D'Aiello A; Elkind R; Sakalian S; Fehn K; Wright K; Abreu M; Townsend-Nugent L; Chambers N; Mathew R; Binakaj D; Nelson R; Palesi C; Paroder M; Uehlinger J; Wang Y; Shi Y; Zang X; Wang H; Nishimura C; Ren X; Steidl UG; Gritsman K; Janakiram M; Kornblum N; Derman O; Mantzaris I; Shastri A; Bartash R; Puius Y; McCort M; Goldfinger M; Bachier-Rodriguez L; Verma A; Braunschweig I; Sica RA
Stem Cell Investig; 2021; 8():18. PubMed ID: 34631871
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.
Berning P; Shumilov E; Maulhardt M; Boyadzhiev H; Kerkhoff A; Call S; Reicherts C; Saidy AO; Aydilek E; Hoffmann M; Novak U; Daskalakis M; Schmitz N; Stelljes M; Wulf G; Bacher U; Lenz G; Pabst T
Hemasphere; 2024 Mar; 8(3):e54. PubMed ID: 38510993
[TBL] [Abstract][Full Text] [Related]
12. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
Albanyan O; Chavez J; Munoz J
Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
[TBL] [Abstract][Full Text] [Related]
14. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
15. Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel.
Fehse B; Badbaran A; Berger C; Sonntag T; Riecken K; Geffken M; Kröger N; Ayuk FA
Mol Ther Methods Clin Dev; 2020 Mar; 16():172-178. PubMed ID: 32055645
[TBL] [Abstract][Full Text] [Related]
16. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
17. Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy.
Seipel K; Abbühl M; Bacher U; Nilius H; Daskalakis M; Pabst T
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297020
[TBL] [Abstract][Full Text] [Related]
18. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
19. CD19-directed CAR T-cell therapy in B-cell NHL.
Kersten MJ; Spanjaart AM; Thieblemont C
Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
[TBL] [Abstract][Full Text] [Related]
20. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
